Novare Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$564K Sell
1,559
-17
-1% -$5.82K 0.04% 141
2026
Q1
$554K Buy
1,576
+277
+21% +$98.7K 0.04% 132
2025
Q4
$425K Hold
1,299
0.03% 148
2025
Q3
$367K Buy
1,299
+320
+33% +$92.8K 0.03% 154
2025
Q2
$273K Buy
979
+300
+44% +$85K 0.02% 174
2025
Q1
$211K Buy
+679
New +$201K 0.02% 185
2024
Q4
Sell
-879
Closed -$283K 187
2024
Q3
$283K Hold
879
0.02% 161
2024
Q2
$275K Hold
879
0.02% 155
2024
Q1
$250K Buy
+879
New +$257K 0.02% 165
2021
Q4
Sell
-1,353
Closed -$288K 162
2021
Q3
$288K Buy
+1,353
New +$311K 0.03% 130

Other funds holding AMGN

Novare Capital Management's AMGN Position: Q2 2026 in Review

Novare Capital Management reduced its Amgen (AMGN) stake by 1.1% in Q2 2026, selling an estimated $5.82K and leaving 1,559 shares worth $564K. The position accounts for 0.04% of the portfolio, ranked #141.

Novare Capital Management first reported a position in AMGN in Q3 2021 and has held it in 10 quarters since. 3,156 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Novare Capital Management held 1,559 shares of Amgen worth $564K as of Q2 2026.
  • Novare Capital Management sold 17 Amgen shares in Q2 2026, an estimated $5.82K.
  • Amgen made up 0.04% of Novare Capital Management's portfolio in Q2 2026, its #141 holding.
  • Novare Capital Management first reported a position in Amgen in Q3 2021 and has held it in 10 quarters since.
  • 3,156 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Novare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.